Yahoo
HKSE - Delayed Quote HKD

Jacobson Pharma Corporation Limited (2633.HK)

1.050 +0.005 (+0.48%)
At close: 3:13:41 PM GMT+8
Dividend
2633.HK announced a cash dividend of HKD 0.047 with an ex-date of Sep. 7, 2026
Chart Range Bar
Loading chart for 2633.HK
  • Previous Close 1.045
  • Open 1.050
  • Bid 1.045 x --
  • Ask 1.050 x --
  • Day's Range 1.045 - 1.050
  • 52 Week Range 0.980 - 1.530
  • Volume 214,000
  • Avg. Volume 298,451
  • Market Cap (intraday) 2.1B
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) 7.00
  • EPS (TTM) 0.150
  • Earnings Date --
  • Forward Dividend & Yield 0.10 (9.09%)
  • Ex-Dividend Date Sep 7, 2026
  • 1y Target Est 2.51

Jacobson Pharma Corporation Limited, through its subsidiaries, engages in the development, production, marketing, and sale of essential medicines and specialty drugs in Hong Kong, Mainland China, Macau, and internationally. The company offers a portfolio of generic drugs for various therapeutic classes, such as cardiovascular, central nervous, gastrointestinal, respiratory, musculo-skeletal, genito-urinary, anti-infectives, endocrine and metabolic, dermatologicals, and anti-allergics in oral solid and liquid, external liquid, semi-solid, sterile, rectal, and specialized forms. It also provides management and treasury services. Jacobson Pharma Corporation Limited was incorporated in 2016 and is headquartered in Kwun Tong, Hong Kong.

www.jacobsonpharma.com

1,768

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 8/27/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2633.HK
19.23%
HANG SENG INDEX (^HSI)
0.25%

1-Year Return

2633.HK
26.75%
HANG SENG INDEX (^HSI)
1.44%

3-Year Return

2633.HK
87.41%
HANG SENG INDEX (^HSI)
41.10%

5-Year Return

2633.HK
265.89%
HANG SENG INDEX (^HSI)
0.62%

Analyst Insights

View More

Analyst Price Targets

2.51
2.51 Average
1.050 Current
2.51 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 8/26/2026
  • Market Cap

    2.09B

  • Enterprise Value

    2.63B

  • Trailing P/E

    6.92

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.33

  • Price/Book (mrq)

    0.90

  • Enterprise Value/Revenue

    1.68

  • Enterprise Value/EBITDA

    4.81

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.22%

  • Return on Assets (ttm)

    6.72%

  • Return on Equity (ttm)

    12.52%

  • Revenue (ttm)

    1.57B

  • Net Income Avi to Common (ttm)

    301.62M

  • Diluted EPS (ttm)

    0.150

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    419.01M

  • Total Debt/Equity (mrq)

    38.92%

  • Levered Free Cash Flow (ttm)

    102.03M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: